Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

1921. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. (PubMed)

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. In a randomised phase I trial of a recombinant vaccina virus vaccine expressing the gp160 envelope gene of the human immunodeficiency virus (HIVAC-1e) 35 healthy, HIV-seronegative males, 31 of whom had a history of smallpox immunisation and 4 of whom were vaccinia naive, were vaccinated and then boosted 8 weeks later with HIVAC-1e or standard NY strain vaccinia virus. The frequency (...) , duration, and titre of virus isolation from the vaccination site and occurrence of local side-effects were similar between the two groups of vaccinees. Vaccinia-naive (vac-n) subjects shed virus from the vaccination site for longer and at a higher titre than did vaccinia-primed (vac-p) individuals (19 vs 7 days and 10(7) vs 10(5) pfu/ml, respectively). In-vitro T-cell proliferative responses to one or more HIV antigen preparations developed in 13 of 16 vaccinia-primed subjects inoculated with HIVAC-1e

1991 Lancet

1922. Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. (PubMed)

Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. OBJECTIVE--The purpose of this study was to determine whether the beneficial effects of zidovudine seen overall in two recently completed placebo-controlled clinical trials are also apparent in blacks, Hispanics, women, and intravenous drug users. DESIGN--Two double-blind placebo-controlled randomized clinical trials, protocols 016 and 019, conducted by the AIDS Clinical Trials Group. SETTING

1991 JAMA

1923. HIV in the health care workplace

HIV in the health care workplace HIV in the health care workplace HIV in the health care workplace Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Office of Technology Assessment. HIV in the health care workplace. U. S (...) . Congress. Office of Technology Assessment (OTA). HIV related issues. Background paper; 7. OTA-BP-H-90. 1991 Authors' objectives To examine evidence of the risk of HIV transmission in the health care workplace and discuss the policy implications of the U. S. Centers for Disease Control (CDC) guidelines and congressional actions in response to this risk. Authors' conclusions The report analyzes the issues related to CDC's guidelines for Congressional consideration. Project page URL Indexing Status

1991 Health Technology Assessment (HTA) Database.

1924. Capacity of HIV1 p24 antigen screening to reduce the current residual risk of contracting HIV infection following transfusion

Capacity of HIV1 p24 antigen screening to reduce the current residual risk of contracting HIV infection following transfusion Capacity of HIV1 p24 antigen screening to reduce the current residual risk of contracting HIV infection following transfusion Capacity of HIV1 p24 antigen screening to reduce the current residual risk of contracting HIV infection following transfusion Fleurette F, Durieux, P Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fleurette F, Durieux, P. Capacity of HIV1 p24 antigen screening to reduce the current residual risk of contracting HIV infection following transfusion. Paris: L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) 1991: 20 Authors' objectives Given that a screening procedure to detect Human Immunodeficiency Virus (HIV) itself rather than the immune response, was made available

1991 Health Technology Assessment (HTA) Database.

1925. Cost-effectiveness of low dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection

Cost-effectiveness of low dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection Cost-effectiveness of low dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection Cost-effectiveness of low dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection Schulman K A, Lynn L A, Glick H A, Eisenberg J M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Low dose zidovudine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Asymptomatic HIV-infected people with CD4+ lymphocyte counts. Setting The study was carried out in the USA. Dates to which data relate

1991 NHS Economic Evaluation Database.

1926. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis

Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis Freedberg K A, Tosteson A N, Cohen C J, Cotton D J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Dapsone, trimethoprim-sulfamethoxazole, aerosolized pentamidine. Type of intervention Secondary primary prevention. Economic study type Cost-effectiveness analysis. Study population HIV-infected people with CD4

1991 NHS Economic Evaluation Database.

1927. Inhibition of HIV progression by dithiocarb. German DTC Study Group. (PubMed)

Inhibition of HIV progression by dithiocarb. German DTC Study Group. 60 patients with HIV-1 infection in Walter Reed stages 2-4 were randomised to treatment with intravenous or oral dithiocarb (diethyldithiocarbamate, DTC) or placebo for 24 weeks in a paired double-blind design. 55 patients were evaluable at the end of the study: no patient who had received DTC but 6 placebo patients had AIDS, a significant difference. Significantly delayed disease progression was observed in the intravenous

1990 Lancet

1928. The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection

The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Office of Technology Assessment. The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection. Washington DC: U. S. Congress. Office of Technology Assessment (OTA) 1990: 160 Authors' objectives To examine evidence on the effectiveness of drug abuse treatment, to evaluate its potential role in reducing the spread of HIV, and to compare it to other approaches to HIV prevention among

1990 Health Technology Assessment (HTA) Database.